Conference
Meta-analysis: Risk of congestive heart failure (CHF) in selected targeted agents.
Abstract
64
Background: Congestive heart failure (CHF) is among the most serious cardiovascular side effects of targeted agents (TA) impacting the clinical outcomes (including survival) of cancer patients on this therapy. Although clinical trials have reported this toxicity, often sample sizes are small and systemic evaluations are lacking. The objective of this study is to estimate risk and severity of CHF due to selected TAs. …
Authors
Escalante CP; Elting LS; Halm J; Zalpour A; Bossi P; Yusuf S; Brito-Dellan N; Sahai S; Bhadriraju S; Rouleau T
Volume
33
Pagination
pp. 64-64
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
October 10, 2015
DOI
10.1200/jco.2015.33.29_suppl.64
Conference proceedings
Journal of Clinical Oncology
Issue
29_suppl
ISSN
0732-183X